Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jody C. Chuang"'
Autor:
Peter A. Jones, Victor E. Marquez, Peter W. Laird, Tiffany Long, Louis Dubeau, Allen S. Yang, Gerda Egger, Hyang-Min Byun, Jody C. Chuang, Christine B. Yoo
Supplementary Figures 1-4 from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b9c7b65fcec0b9c4d0f504a715cd471
https://doi.org/10.1158/1940-6207.22523032.v1
https://doi.org/10.1158/1940-6207.22523032.v1
Autor:
Peter A. Jones, Victor E. Marquez, Peter W. Laird, Tiffany Long, Louis Dubeau, Allen S. Yang, Gerda Egger, Hyang-Min Byun, Jody C. Chuang, Christine B. Yoo
Recent successes in the application of epigenetic drugs for the treatment of myelodysplastic syndrome have raised questions on the safety of long-term administration of DNA methylation inhibitors. We treated preweaned cancer prone ApcMin/+ (Min) mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1916351bf1cdaca0cb562e260ee88bb1
https://doi.org/10.1158/1940-6207.c.6543562
https://doi.org/10.1158/1940-6207.c.6543562
Autor:
Peter A. Jones, Victor E. Marquez, Peter W. Laird, Tiffany Long, Louis Dubeau, Allen S. Yang, Gerda Egger, Hyang-Min Byun, Jody C. Chuang, Christine B. Yoo
Perspective from Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24eedd0ad2de043705febf74e65d5072
https://doi.org/10.1158/1940-6207.22523035.v1
https://doi.org/10.1158/1940-6207.22523035.v1
Autor:
Jody C. Chuang, A. Dimitrios Colevas, Matthew A. Gubens, Christelle Clément-Duchêne, Konstantin H. Dragnev, Wallace Akerley, Heather A. Wakelee, Melanie San Pedro-Salcedo, Corey J. Langer, Mark A. Socinski
Publikováno v:
Journal of Thoracic Disease. 10:219-227
Background: Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival bene t with the use of angiogenesis
Autor:
Jody C. Chuang, Joel W. Neal
Publikováno v:
Cancer. 123:2798-2801
Autor:
Jane Huang, Maximilian Diehn, Joel W. Neal, Heather A. Wakelee, Henning Stehr, Ying Liang, Jody C. Chuang, Millie Das
Publikováno v:
Journal of Thoracic Oncology. 12:833-842
Introduction Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 ) (also called HER2 ) has long been recognized as an oncogenic driver in some breast and gastroesophageal cancers in which amplification of this gene confers sensitivity to treatment with Erb
Publikováno v:
Hematology/Oncology Clinics of North America. 31:31-44
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non-small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-an
Publikováno v:
Expert Opinion on Pharmacotherapy. 17:989-993
Major advances have been made since the discovery of driver mutations and their targeted therapies, especially in the treatment of patients with epidermal growth factor receptor (EGFR) mutations. Despite their initial efficacy in the majority of the
Publikováno v:
Current treatment options in oncology. 18(12)
Personalized targeted therapy has emerged as a promising strategy in lung cancer treatment, with current attention focused on elucidation and detection of oncogenic drivers responsible for tumor initiation and maintenance and development of drug resi
Publikováno v:
Lung Cancer. 90:1-7
Tyrosine kinase inhibitors (TKIs) against targetable mutations such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are highly effective in treating advanced stage lung cancers harboring such mutations. Questions remai